#C1203N 3CLPro E166G Expression Kit

3CL^pro (M^pro) E166G mutation Expression Kit

The E166G mutation seems to be associated with reduced enzymatic activity and increased Ki values for nirmatrelvir, according to Hu et al. and Tan et al. (Tan et al. 2023; Hu et al. 2023) In both studies, E166G exhibited a 7.4-fold reduction in enzymatic activity, and a 16.4-fold increase in the Ki value for nirmatrelvir (Tan et al. 2023; Hu et al. 2023). Additionally, this mutation has been detected in patients and documented in the GISAID database (Shu and McCauley 2017).

• Identify protease inhibitors that maintain efficacy against the E166V mutation
• Easy co-expression with our 3CLglow and 3CLglowUp sensors
• Cost effective screening with minimal safety requirements (BSL-1)

Materials in the Kit:

• 3CL^pro E166G in BacMam
• Sodium Butyrate, 500 mM in H₂O

References:

Hu, Y., Lewandowski, E. M., Tan, H., Zhang, X., Morgan, R. T., Zhang, X., Jacobs, L. M., Butler, S. G., Gongora, M. V., Choy, J., Deng, X., Chen, Y., & Wang, J. (2023). Naturally occurring mutations of SARS-COV-2 main protease confer drug resistance to Nirmatrelvir. ACS Central Science, 9(8), 1658–1669. https://doi.org/10.1021/acscentsci.3c00538

Shu, Y., & McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data – from vision to reality. Eurosurveillance, 22(13). https://doi.org/10.2807/1560-7917.es.2017.22.13.30494

Tan, B., Joyce, R., Tan, H., Hu, Y., & Wang, J. (2023). SARS-COV-2 main protease drug design, Assay Development, and Drug Resistance Studies. Accounts of Chemical Research, 56(2), 157–168. https://doi.org/10.1021/acs.accounts.2c00735